ReviewThe Journal of allergy and clinical immunology2015
The future of biologics: applications for food allergy.
Review in The Journal of allergy and clinical immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Positive rate of wheat allergens in the Chinese allergic population: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- IgG in the control of FcεRI activation: a battle on multiple fronts.Frontiers in immunology · 2023Review
- An Unusual Case of Multiple Food Allergies Comorbid with Multiple Chemical Sensitivity: A Case Report.Journal of asthma and allergy · 2021Article
- Mucosal Nanoemulsion Allergy Vaccine Suppresses Alarmin Expression and Induces Bystander Suppression of Reactivity to Multiple Food Allergens.Frontiers in immunology · 2021Article
- New Perspectives in Food Allergy.International journal of molecular sciences · 2020Review
- Delivery of allergen powder for safe and effective epicutaneous immunotherapy.The Journal of allergy and clinical immunology · 2020Article
- IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy.Frontiers in immunology · 2020Review
- Food Allergies: Current and Future Treatments.Medicina (Kaunas, Lithuania) · 2019Review
- CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.The Journal of clinical investigation · 2019Article
- Recruiting CD33 on mast cells to inhibit IgE-mediated mast cell-dependent anaphylaxis.The Journal of clinical investigation · 2019Article
- Inhibition of soluble epoxide hydrolase attenuates eosinophil recruitment and food allergen-induced gastrointestinal inflammation.Journal of leukocyte biology · 2018Article
- Spontaneous food allergy in WasAllergy · 2017Article
- The current state of food allergy therapeutics.Human vaccines & immunotherapeutics · 2017Review
- Article
- Novel Biologicals for the Treatment of Allergic Diseases and Asthma.Current allergy and asthma reports · 2016Review
- New insights into basophil heterogeneity.Seminars in immunopathology · 2016Review
- Laser-facilitated epicutaneous immunotherapy to IgE-mediated allergy.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- Pearls and Pitfalls in Diagnosing IgE-Mediated Food Allergy.Current allergy and asthma reports · 2016Review
- Current and Emerging Therapies for IgE-Mediated Food Allergy.Current allergy and asthma reports · 2016Review
- Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.British journal of pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Allergic diseases affect millions worldwide, with growing evidence of an increase in allergy occurrence over the past few decades. Current treatments for allergy include corticosteroids to reduce inflammation and allergen immunotherapy; however, some subjects experience treatment-resistant inflammation or adverse reactions to these treatments, and there are currently no approved therapeutics for the treatment of food allergy. There is a dire need for new therapeutic approaches for patients with poorly controlled atopic diseases and a need to improve the safety and effectiveness of allergen immunotherapy. Improved understanding of allergy through animal models and clinical trials has unveiled potential targets for new therapies, leading to the development of several biologics to treat allergic diseases. This review focuses on the mechanisms that contribute to allergy, with an emphasis on future targets for biologics for the treatment of food allergy. These biologics include immunotherapy with novel anti-IgE antibodies and analogs, small-molecule inhibitors of cell signaling, anti-type 2 cytokine mAbs, and TH1-promoting adjuvants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.